Zheng Quan Shi Bao Wang·2025-07-29 08:48Core Insights - The cell immunotherapy sector saw a 2.42% increase, ranking 6th among concept sectors, with 42 stocks rising, led by Ruizhi Pharmaceutical with a 20% limit-up [1] - Major inflows were observed in the cell immunotherapy sector, with a net outflow of 239 million yuan, while 31 stocks experienced net inflows, with Ruizhi Pharmaceutical leading at 235 million yuan [1][2] Group 1: Sector Performance - The cell immunotherapy concept had a 2.42% increase, with notable performers including Ruizhi Pharmaceutical (20.02%), Sanyuan Gene (20.76%), and Haitai Biological (15.28%) [1] - The sector's performance was contrasted by declines in stocks like Saili Medical (-4.62%), Zexin Pharmaceutical (-3.47%), and Xue Rong Biological (-2.39%) [1] Group 2: Fund Flow Analysis - Ruizhi Pharmaceutical, Jinyu Medical, and Chengda Pharmaceutical had the highest net inflow ratios at 15.31%, 10.34%, and 9.67% respectively [2] - The top stocks by net inflow included Ruizhi Pharmaceutical (234.82 million yuan), Hanyu Pharmaceutical (73.39 million yuan), and Jiu Zhitang (49.52 million yuan) [2][3] Group 3: Stock Performance - Stocks like Haitai Biological and Yuedong Pharmaceutical showed significant gains, with Haitai Biological rising by 15.28% and Yuedong Pharmaceutical by 9.96% [1][4] - Conversely, stocks such as Saili Medical and Zexin Pharmaceutical faced notable declines, with Saili Medical down by 4.62% and Zexin Pharmaceutical by 3.47% [5]